European Commission grants marketing approval for Cerdelga (Eliglustat) capsules

The Gauchers Association are pleased to announce that the European Commission (EC) has granted marketing approval for Cerdelga (Eliglustat) capsules, an oral therapy indicated in the European Union for the long term treatment of adult patients with Gaucher Disease type I, who are poor, intermediate metabolisers or extensive metabolisers.

The new treatment will be subject to an appraisal by the National Institute of Health and Care Excellence (NICE).  The Gauchers Association are working closely with NICE and Genzyme on this process and will update patients on the progress of this as and when we know more about the timelines involved.